1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Nicox SA.
  6. News
  7. Summary
    COX   FR0013018124

NICOX SA.

(COX)
  Report
Real-time Euronext Paris  -  11:35 2022-07-04 am EDT
1.718 EUR   -0.12%
06/22Nicox Extraordinary General Meeting of July 11, 2022
GL
06/22Nicox Extraordinary General Meeting of July 11, 2022
AQ
06/15NICOX : Suggested agenda and summary of the resolutions submitted to the approval of the Extraordinary shareholder meeting (translation for information purposes)
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Nicox: 2022 Ordinary Shareholder Meeting

05/04/2022 | 01:30am EDT
Press Release
Nicox: 2022 Ordinary Shareholder Meeting


May 4, 2022 – release at 7:30 am CET
Sophia Antipolis, France



Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, convenes an ordinary shareholder meeting on Tuesday June 14, 2022 at 2:00 pm CEST in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis - France.



The documents mentioned in articles R.22.10-23 of the French Code de commerce, including a proxy voting form, will be sent to the shareholders upon written request. These documents will also be made available to shareholders at the headquarters of the Company and on its website (www.nicox.com) by May 24, 2022.



Shareholders may vote by proxy, by internet or by attending the shareholder meeting in person. A guide explaining how to vote, and notably how to vote by internet, will be posted on Nicox’s website by May 24, 2022. Shareholders may also contact the Company’s Investor Relations team at ag2022nicox@nicox.com for any question on the voting process.



In the event the quorum is not reached on first call, Nicox will convene an ordinary shareholder meeting on a second call on Tuesday June 28, 2022 at 2:00 pm CEST in the offices of BuroClub - Drakkar 2 - Bâtiment D - 2405 route des Dolines - 06560 Valbonne Sophia Antipolis – France.


About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for dry eye disease. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment C: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Analyst coverage


Bryan, Garnier & Co         Dylan van Haaften        Paris, France
Edison Investment Research        Pooya Hemami        London, UK
H.C. Wainwright & Co        Yi Chen        New York, U.S.
Kepler Cheuvreux        Arsene Guekam        Paris, France
 
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

 

Contacts


Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com


Investor & Media
United States & Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
svonderweid@lifesciadvisors.com
Forward-Looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2021’ filed with the French Autorité des Marchés Financiers (AMF) on April 29, 2022 which is available on Nicox’s website (www.nicox.com).
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

 

Attachment

  • EN_AGO 2022 - avis de réunion_20220504_F

Primary Logo

Source: NICOX

2022 GlobeNewswire, Inc., source Press Releases

All news about NICOX SA.
06/22Nicox Extraordinary General Meeting of July 11, 2022
GL
06/22Nicox Extraordinary General Meeting of July 11, 2022
AQ
06/15NICOX : Suggested agenda and summary of the resolutions submitted to the approval of the E..
PU
06/15NICOX : How to participate in the Extraordinary shareholder meeting
PU
06/14NICOX : 2022 Ordinary Shareholder Meeting
GL
06/14NICOX : 2022 Ordinary Shareholder Meeting
GL
06/03NICOX : 2022 Extraordinary Shareholder Meeting
GL
06/03NICOX : 2022 Extraordinary Shareholder Meeting
AQ
06/03Ophthalmology Group Nicox To Release Data From Late-stage Glaucoma Drug Trial In Novemb..
MT
06/03Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to Nov..
GL
More news
Financials
Sales 2022 9,03 M 9,41 M 9,41 M
Net income 2022 -20,3 M -21,2 M -21,2 M
Net cash 2022 2,49 M 2,59 M 2,59 M
P/E ratio 2022 -3,66x
Yield 2022 -
Capitalization 74,3 M 77,4 M 77,4 M
EV / Sales 2022 7,95x
EV / Sales 2023 6,44x
Nbr of Employees 33
Free-Float 89,1%
Chart NICOX SA.
Duration : Period :
Nicox SA. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NICOX SA.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 1,72 €
Average target price 11,50 €
Spread / Average Target 569%
EPS Revisions
Managers and Directors
Andreas Rutger Segerros Chief Executive Officer
Sandrine Gestin Vice President-Finance
Michele Garufi Chairman
Doug Hubatsch Chief Scientific Officer
Jean-François Labbé Independent Director
Sector and Competitors
1st jan.Capi. (M$)
NICOX SA.-32.68%77
MERCK KGAA-27.00%74 935
KYOWA KIRIN CO. LTD.-3.19%12 062
SK BIOPHARMACEUTICALS CO., LTD.-25.62%4 240
BETTA PHARMACEUTICALS CO., LTD.-26.86%3 452
YUHAN CORPORATION-8.21%2 930